• iRadimed recently reported record full-year 2025 results and strong first-quarter 2026 performance, alongside FDA 510(k) clearance for its upgraded MRidium 3870 MRI IV infusion pump and an increase in its quarterly cash dividend.
• This combination of stronger profitability, a cleared next-generation pump expected to spur replacement demand, and a higher dividend highlights management’s confidence in the company’s cash generation profile.
• We’ll now examine how FDA clearance of the MRidium 3870 and management’s upbeat guidance reshape IRADIMED’s broader investment narrative.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

IRADIMED Investment Narrative Recap

To own IRADIMED, you need to believe MRI‑compatible pumps and monitors can remain essential tools in high‑acuity imaging suites, and that the company can steadily convert that demand into durable, high‑margin cash flows. The recent record 2025 results, strong Q1 2026, and 510(k) clearance for the MRidium 3870 support the near‑term replacement cycle catalyst, while execution on scaling the new pump and managing a concentrated product portfolio still looks like the key risk.

Among the latest updates, the FDA clearance and launch of the MRidium 3870 stand out as most relevant. This device sits at the center of the expected upgrade cycle, with the new configurations carrying list prices more than double the prior generation and management guiding to higher average selling prices, which ties directly into the story that margins and cash generation will depend heavily on how smoothly customers transition to this next‑generation platform.

Yet while the 3870 story is encouraging, investors should also be aware of the concentration risk around a single product family and how...

IRADIMED's narrative projects $113.8 million revenue and $32.0 million earnings by 2029. This requires 9.7% yearly revenue growth and about a $8.4 million earnings increase from $23.6 million today.

Uncover how IRADIMED's forecasts yield a $118.00 fair value, a 24% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$71 to US$118 per share, highlighting how far apart individual views can be. Against that backdrop, the 3870 pump launch as a key catalyst and the company’s narrow product focus are worth weighing carefully as you compare these different expectations for IRADIMED’s future performance.

Explore 3 other fair value estimates on IRADIMED - why the stock might be worth 25% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your IRADIMED research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free IRADIMED research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IRADIMED's overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.